The Food and Drug Administration has approved Juvmo, the brand name for tavapadon, to treat Parkinson’s disease in adults. The action adds a new oral medicine to the treatment landscape for a progressive neurological disorder whose motor symptoms can include tremor, slowed movement and stiffness.
The FDA records Juvmo as its 43rd novel-drug approval of 2026, with an approval date of September 25. On its 2026 novel-drug approvals list, the agency identifies tavapadon as the active ingredient and Parkinson’s disease in adults as the approved use. “Novel” in this FDA program means a drug had not previously been approved or marketed in the United States; it does not, by itself, establish that a medicine is better than existing treatments.
Detailed findings from the clinical program suggest tavapadon improved several measured outcomes over 26 weeks, both when used alone and when added to oral levodopa. But the information publicly summarized so far leaves important questions about the size of those benefits, how the drug compares directly with established Parkinson’s therapies, and its longer-term safety profile.
What the pivotal studies found
Juvmo is an AbbVie tablet available in 5-milligram, 10-milligram and 15-milligram strengths, along with a titration pack containing 0.25-milligram and 1-milligram tablets, according to Medscape’s report on the approval. The report said the FDA decision was supported by three pivotal phase 3 trials in the TEMPO program.
Two of those studies, TEMPO 1 and TEMPO 2, tested tavapadon as monotherapy. TEMPO 1 enrolled 529 patients and TEMPO 2 enrolled 304. In each trial, participants taking tavapadon had a statistically significant reduction at 26 weeks in a combined score from Parts II and III of the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale, compared with placebo. Those sections assess everyday experiences of motor symptoms and clinician-rated motor examination, respectively.
A third study, TEMPO 3, evaluated tavapadon at doses of 5 to 15 milligrams as an add-on to oral levodopa. At 26 weeks, the tavapadon-plus-levodopa group had more daily “on” time and less “off” time than the placebo-plus-levodopa group, Medscape reported. In Parkinson’s care, on time generally refers to periods when medication is providing useful control of symptoms; off time refers to intervals when symptoms return or become less controlled.
Because these were placebo-controlled comparisons, they can support the conclusion that tavapadon caused improvements in the outcomes measured over the trials’ 26-week period among the patients studied. The public account does not provide the effect sizes, confidence intervals, full eligibility criteria, discontinuation rates or detailed subgroup findings needed to judge how large or consistent the benefits were across different groups of patients.
The report also described an 85-week open-label extension, TEMPO-4, in which tavapadon was associated with sustained efficacy and treatment-emergent adverse events were characterized as nonserious and mild or moderate. Open-label extensions can offer useful follow-up information, but they are less reliable than blinded, controlled trials for establishing a treatment’s comparative long-term benefit or safety. Participants and investigators know which treatment is being taken, and there is no concurrent placebo group to account for changes over time.
A different dopamine-receptor target
Medscape, citing AbbVie’s description of the product, called tavapadon the first and only FDA-approved selective D1/D5 receptor agonist for Parkinson’s disease. That characterization is distinct from the FDA’s confirmation that Juvmo is a novel drug. The agency’s novel-drug list verifies that tavapadon is new to the U.S. market, but it does not independently describe the medicine as first in its receptor class.
Dopamine signaling is central to the motor symptoms of Parkinson’s disease. According to the report, commonly used dopamine agonists primarily act at D2 and D3 receptors, while tavapadon selectively targets D1 and D5 receptors. The differing receptor profile may help explain why the drug is being viewed as a new pharmacological approach, but a new mechanism does not establish clinical superiority over other medicines. Direct head-to-head comparative trial evidence was not included in the available account of the approval.
Levodopa remains a core treatment for many people with Parkinson’s disease. Over time, however, some patients experience fluctuations in symptom control, including off periods, or involuntary movements known as dyskinesia. The TEMPO 3 result is therefore clinically relevant as evidence that tavapadon may be used alongside oral levodopa to address daily symptom fluctuations. It does not show that the drug prevents disease progression or replaces levodopa for all patients.
Safety and unanswered questions
Reported common adverse events differed depending on whether tavapadon was used alone or with levodopa. In monotherapy studies, Medscape listed nausea, headache, dizziness, fatigue, altered taste, vomiting, dry mouth and anxiety. In the levodopa add-on study, the reported events included nausea, dyskinesia, dizziness, headache, hallucinations and orthostatic hypotension, a drop in blood pressure upon standing that can cause lightheadedness or fainting.
Those findings are not a complete substitute for the current FDA-approved prescribing information, which clinicians use for dosage, warnings, contraindications, interactions and monitoring considerations. The FDA’s approval page directs readers to Drugs@FDA for the most current label. Whether Juvmo is appropriate for a particular person will depend on symptoms, other medicines, medical history and tolerance of potential side effects.
Medscape also reported that a draft review by the Institute for Clinical and Economic Review described tavapadon’s net health benefit as promising but inconclusive. The review raised particular concern that 26-week controlled trials may be too brief to draw firm conclusions about impulse-control behaviors, a potential issue with dopamine-directed therapies. Less common harms and delayed effects can become clearer only with longer follow-up and wider use after approval.
The timing of the regulatory record is also worth separating from the public reports about it. The FDA gives September 25 as the approval date, while its novel-drug page carries a September 28 publication or update date; Medscape’s account was also published September 28. For patients and clinicians, the next practical details will come from the full label, treatment access and experience using tavapadon outside the tightly defined setting of clinical trials.